Patent · US Active

NLRP3 modulators

US12037344B2 · kind B2 · utility

0Cited by

7References

34Claims

0Family size

Assignee

Innate Tumor Immunity, Inc. · US

Inventors

Yong Zhang · Princeton, US
Ashvinikumar V. Gavai · Princeton Junction, US
Andrew F. Donnell · Plainsboro, US
Shomir Ghosh · Brookline, US
William R. Roush · West Jupiter, US
Prasanna Sivaprakasam · Lawrenceville, US
Steven P. Seitz · Swarthmore, US
Jay A. Markwalder · New London, US

Key dates

Filing date	Apr 24, 2019
Grant date	Jul 16, 2024
Priority date	—
Expiry date	Sep 25, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D513/04
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The present invention provides compounds of Formula (I): wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.